Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Loomba

Showing results (31-40 of 747) with videos related to

Pageof 75
Sort By:
Alimentary Pharmacology & Therapeutics|February 15, 2025
Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol-Authors' ReplyFederica Tavaglione, Rohit Loomba
Hepatology (Baltimore, Md.)|July 21, 2017
ReplySiddharth Singh, Rohit Loomba
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 5, 2017
Do Zones of Hepatic Steatosis Associate With Subtypes and Progression of Nonalcoholic Fatty Liver Disease in Children?Veeral Ajmera, Rohit Loomba
Journal of Hepatology|December 1, 2025
Reply to: "Limited clinical utility of serum-based ELISA PEth compared with whole-blood LC-MS/MS PEth to quantify alcohol consumption"Federica Tavaglione, Rohit Loomba
Current Hepatology Reports|October 27, 2015
Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?Ahilan Arulanandan, Rohit Loomba
Clinical Liver Disease|June 13, 2019
Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkersMazen Noureddin, Rohit Loomba
Advances in Therapy|January 4, 2014
Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD)Iliana Doycheva, Rohit Loomba
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 23, 2026
Clinical Use of Noninvasive Testing for Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver DiseaseMaria Mironova, Rohit Loomba
Gastroenterology|June 11, 2026
Reply to "Generalizability of the MetALD-ALD Prediction Index in Asian populations"Federica Tavaglione, Rohit Loomba
Journal of Hepatology|July 30, 2023
Reply to: "Non-invasive testing for advanced fibrosis in patients with diabetes with fatty liver disease needs further evaluation of cut-off values"Veeral Ajmera, Rohit Loomba
Pageof 75

Showing results (31-40 of 747) with videos related to

Sort By:
Pageof 75
Alimentary Pharmacology & Therapeutics|February 15, 2025
Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol-Authors' ReplyFederica Tavaglione, Rohit Loomba
Hepatology (Baltimore, Md.)|July 21, 2017
ReplySiddharth Singh, Rohit Loomba
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 5, 2017
Do Zones of Hepatic Steatosis Associate With Subtypes and Progression of Nonalcoholic Fatty Liver Disease in Children?Veeral Ajmera, Rohit Loomba
Journal of Hepatology|December 1, 2025
Reply to: "Limited clinical utility of serum-based ELISA PEth compared with whole-blood LC-MS/MS PEth to quantify alcohol consumption"Federica Tavaglione, Rohit Loomba
Current Hepatology Reports|October 27, 2015
Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?Ahilan Arulanandan, Rohit Loomba
Clinical Liver Disease|June 13, 2019
Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkersMazen Noureddin, Rohit Loomba
Advances in Therapy|January 4, 2014
Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD)Iliana Doycheva, Rohit Loomba
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 23, 2026
Clinical Use of Noninvasive Testing for Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver DiseaseMaria Mironova, Rohit Loomba
Gastroenterology|June 11, 2026
Reply to "Generalizability of the MetALD-ALD Prediction Index in Asian populations"Federica Tavaglione, Rohit Loomba
Journal of Hepatology|July 30, 2023
Reply to: "Non-invasive testing for advanced fibrosis in patients with diabetes with fatty liver disease needs further evaluation of cut-off values"Veeral Ajmera, Rohit Loomba
Pageof 75